DGKK and fragile X syndrome: In this study, we provide evidence that neuron‐targeted expression of a modified DGKk enzyme with an AAVRh10‐based gene therapy approach is able to provide long‐term correction of disease‐relevant behavioral abnormalities of the young adult Fmr1‐KO mouse model of FXS (Appendix Table S2).